Market Overview

Bank of America Maintains Buy Rating on Auxilium Pharmaceuticals


Bank of America is maintaining is Buy rating on shares of Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL).

“We lowered our sales estimates for Testim based on recent IMS trends and Xiaflex based on a more conservative ramp,” Bank of America writes. “Based on the changes, we lowered 2011E revenue to $262mn (from $270mn) and 2012E revenue to $336mn (from $369mn). Our new 2011E EPS is -$0.75 (from -$0.77) and 2012E EPS is $0.22 (from $0.61).

“Our DCF-based PO is unchanged at $30. We are maintaining our Buy rating as we continue to believe that Xiaflex has significant sales potential and that utilization will steadily grow over time.”

Auxilium Pharmaceuticals closed Wednesday at $22.39.

Posted-In: Auxilium Pharmaceuticals Bank of AmericaAnalyst Ratings


Related Articles (AUXL)

View Comments and Join the Discussion!

Latest Ratings

TOLGoldman SachsInitiates Coverage On42.0
KBHGoldman SachsInitiates Coverage On36.0
YEXTSunTrust Robinson HumphreyMaintains28.0
LHCGSunTrust Robinson HumphreyMaintains160.0
DLRSunTrust Robinson HumphreyMaintains140.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Piper Jaffray Reports On YHOO In Analyst Day Preview

Forex - Dollar mixed vs. rivals as markets seek direction